Prevalence of red blood cell antibodies in whole blood donors: A single-centre experience in north India

Archana Solanki, Tulika Chandra & Ashutosh Singh

Department of Transfusion Medicine, King George’s Medical University, Lucknow, Uttar Pradesh, India

Received February 15, 2019

Background & objectives: Blood transfusion therapy involves multiple steps to ensure selection of safe blood component for transfusion. This includes testing for infectious markers, full ABO compatibility, free from any clinically significant red cell antibodies and acceptable donor’s red cell survival rates without destruction of recipient’s red cells. The red cell antibodies present in healthy blood donors can cause severe haemolytic transfusion reaction, especially in massive blood transfusion recipients and paediatric patients. Hence, screening of red cell antibodies in donor blood is important to provide compatible blood products and to avoid haemolytic transfusion reactions in susceptible patient population. This study was planned to assess prevalence, aetiology and type of unexpected red cell antibodies in a large number of whole blood donor population in north India.

Methods: This three-year prospective observational study included blood donor samples for antibody screening from January 2015 to December 2017. A total of 166,803 healthy blood donors including 156,128 (93.6%) males and 10,675 (6.4%) females were screened.

Results: The prevalence of red cell antibodies was 0.17 per cent in our donor population. Of the total 286 donors with red cell antibodies, 248 (86.7%) had alloantibodies, 30 (10.5%) had autoantibodies and eight donors (2.8%) showed positive antibody screening with inconclusive results.

Interpretation & conclusions: Alloimmunization to red cell antigens is a challenging task for current transfusion practices. The antibody screening in blood donors may improve the quality and safety of blood transfusion in the recipients. It also reduces the risk of complications from incompatible blood transfusions.

Key words Alloantibody identification - antibody screening - blood transfusion safety - haemolytic transfusion reaction - red blood cell panel - red cell alloimmunization - whole blood donors

The International Society of Blood Transfusion recognizes 360 red cell antigen specificities, of which 322 belong to one of the 36 blood group systems. A single gene or cluster of two or three closely-linked homologous genes represents each blood group system. There are four categories of blood group antigens: blood group systems (322 antigens in 36 blood group systems); 700 series low prevalence (17 antigens); 901 series high prevalence (7 antigens) and 200 series collections (14 antigens in 5 collections). Normally, anti-A and anti-B are the only red cell antibodies present in human plasma and known as...
During the study period, a total of 166,803 healthy blood donors including 156,128 (93.6%) males and 10,675 (6.4%) females were screened for the presence of red cell antibodies.

Initially, antibody screening of all blood donors was performed using commercially available single vial of two pooled donors on a fully automated platform [Diagast, qwalys, hema-screen, a fully automated walk-away random access immunohaematology analyzer based on erythrocyte magnetized (EM) technology, 251 Avenue Eugène Avinée, France]. Positive serum samples were further investigated to identify their specificity by commercially available three and 11 red cell panels along with auto-control (Diagast, Hemaident, Avenue Eugène Avinée, France) as per the manufacturer’s instructions. These pre-magnetized panels expressed homozygous antigen profiles of 23 clinically significant antigens including Rh, Kell, Kidd, Duffy, Lewis, MNS, Lutheran, PI blood group systems. The antigens in 11 cell panel were D, C, E, c, e, C*, K, k, kp, kp', Fy'a, Fy'b, Jk', Le', Le, P1, M, N, S, S, Lu', and Lu'b. Antibody detection results were considered positive depending on the reactivity observed in the form of agglutination or haemolysis. The clinical significance of an antibody was determined by its reactivity at different temperature (4, 22 and 37°C, thermal amplitude) and at different phases such as normal saline or in antihuman globulin serum (AHG) phase. The antibodies reacting at 37°C or in AHG phase were considered clinically significant. In the present study, antibodies against M, N, Le', Le, and P1 were not clinically significant as were of IgM type, reacting in saline phase and not reacting at 37°C or in AHG phase. A total of 120 alloantibodies belonged to the above blood groups. The rest 128 alloantibodies were clinically significant and reacted at 37°C. The antibody specificity was confirmed by using PRBCs of having positive homozygous expression of RBC antigens. The donor’s antigen phenotype and the probability of antibody positivity were also taken into account for the final interpretation of results. A direct antiglobulin test (DAT) was performed in all cases with positive auto-control. Adsorption and elution were performed according to the American Association of Blood Banks technical manual\(^3\) with autoantibody positive donors to rule out any underlying alloantibody. However, no alloantibody was found. As per our institutional policy and standard operating procedure to handle these blood units, the plasma and platelet concentrate of blood donors positive for clinically significant alloantibodies were discarded and PRBC was given to ABO- and Rh-matched recipients. Thus, 128 plasma

Material & Methods

This prospective observational study was conducted in the department of Transfusion Medicine, King George’s Medical University, Lucknow, India, after obtaining approval from the Institutional Ethics Committee. Written informed consent was obtained from all blood donors included in the study. All the blood donors were screened after filling blood donor questionnaire form. This form included basic profile of donors (name, age, sex, address, etc.), any history of blood transfusion, trauma, surgery, drug intake, jaundice, high risk behaviour and any other clinically relevant illness. From all female blood donors, detailed gynaecological and obstetrical history was taken. Blood donor samples for red cell antibody screening were tested from January 2015 to December 2017. During the study period, a total of 166,803 healthy blood donors including 156,128 (93.6%) males and 10,675 (6.4%) females were screened for the presence of red cell antibodies.
anti-M (20.5%) followed by anti-N (11.0%). In the Rh blood group system, the most common antibody was anti-D (7.2%) followed by anti-E (4.0%) (Table III).

**Discussion**

The overall prevalence of red cell antibodies was 0.17 per cent, and the frequency of alloimmunization was 0.15 per cent. Among male donors, the frequency of alloimmunization was 0.14 per cent (211/156,128) and in female blood donors rate of alloantibodies formation was 0.35 per cent (37/10,675). The frequency of alloantibodies was significantly higher in female blood donors [0.35% OR: 0.40; 95% confidence interval (CI): 0.29-0.55, \( P<0.001 \)] compared to male blood donors. Thus, the most common aetiology for red cell antibody formation was pregnancy followed by blood transfusion and of unknown aetiology in many of the blood donors in the study. For inconclusive antibody screening results, the reason could be very low titter, low affinity, in developing stage or may be directed against the antigens not provided in the identification panel.

Antibodies against the MNS blood group system were most common, followed by Rh system. Among the MNS blood group system, the most common alloantibody identified was anti-M (20.5%) followed by anti-N (11.0%). In the Rh blood group system, the most common antibody was anti-D (7.2%) followed by anti-E (4.0%) (Table III).

**Table II. Donor characteristics with positive antibody screening results (n=286)**

| Donors | n (%) |
|--------|-------|
| Gender |       |
| Male   | 244 (85.3) |
| Female | 42 (14.7)  |
| ABO blood group |       |
| A      | 70 (24.5)  |
| B      | 102 (35.7) |
| AB     | 22 (7.7)   |
| O      | 92 (32.1)  |
| Rh blood group |       |
| D positive | 264 (92.3) |
| D negative | 22 (7.7)   |
| History of blood transfusion |       |
| Male   | 5/244 (2.0) |
| Female | 11/42 (26.2) |
| History of pregnancy in female donors |       |
| 39/42 (92.8) |     |

units and 120 platelet concentrates were discarded. If a unit had autoantibody (positive DAT and auto-control), no blood components were prepared and the unit was discarded as a whole blood.

**Statistical analysis:** The data were collected from blood bank records. Data processing was performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Chi-square test was used for statistical analysis and \( P<0.05 \) was considered significant. Odds ratio was also calculated to assess the increased likelihood of alloimmunization in female blood donors as compared to male blood donors.

**Results**

Antibody screening was done in 166,803 healthy blood donors including 156,128 (93.6%) male and 10,675 (6.4%) female donors during the study period. Of these, 31 per cent (n=51,709) were voluntary donors and 69 per cent (n=115,094) were related or replacement donors with age groups ranging from 18 to 65 years. Antibody screening results were positive in 286 cases including 244 male donors and 42 female donors. The overall prevalence of red cell antibodies was 0.17 per cent. Of the total 286 cases, 248 donors (211 males and 37 females i.e., 86.7%) had alloantibodies, 30 donors (26 males and 4 females i.e., 10.5%) had autoantibodies and eight (7 males and 1 female i.e., 2.8%) showed positive antibody screening with inconclusive results (Table I). Among immunized donor group (286), 16 (11 females and 5 males) had a history of previous blood transfusions. In non-immunized donor group (166,517), none had or gave past history of blood transfusion. Thirty nine (39/42) and 688 female donors (688/10,633) had a history of pregnancies in immunized and non-immunized groups, respectively (Table II). No donor had both allo- and autoantibodies. The rate of alloantibodies formation in males was 0.14 per cent (211/156,128) and in female blood donors rate of alloantibodies formation was 0.35 per cent (37/10,675). The frequency of alloantibodies was significantly higher in female blood donors [0.35% OR: 0.40; 95% confidence interval (CI): 0.29-0.55, \( P<0.001 \)] compared to male blood donors.

| Table I. Profile of normal and red cell antibody positive whole blood donors |
|-----------------------------|-----------------------------|
| Blood donors                | Male (%)                    | Female (%)               | Total |
| Total whole blood donors    | 156,128 (93.6)              | 10,675 (6.4)             | 166,803 |
| Alloantibody-positive donors| 211 (85.0)                  | 37 (15.0)                | 248    |
| Autoantibody-positive donors| 26 (86.6)                   | 4 (13.4)                 | 30     |
| Donors with inconclusive results | 7 (87.5)          | 1 (12.5)                 | 8      |
alloimmunization was 0.35 per cent (37/10,675). The higher rate of alloimmunization in females could be attributed to antigenic exposure during pregnancies. Other studies on healthy blood donors showed frequency of alloimmunization from 0.05 to 4.0 per cent. In our study, most frequent alloantibodies identified were of MNS blood group system. M and N antigens are the oldest blood antigens known after the ABO system. Rare examples of anti-M and anti-N have been reported in the literature to cause immediate or delayed haemolytic transfusion reactions and severe haemolytic disease of the foetus and newborn (HDFN). Anti-M is a common antibody usually cold-reacting IgG and is enhanced by serologic testing in an acidic environment. Thus antibodies to antigens in the MNS blood group system are mostly naturally occurring, usually do not react at 37°C, and can be overlooked during pre-transfusion testing. In Rh blood group system, Rh (D) antigen is the most potent immunizing antigen after A and B blood group antigens and capable of causing clinically significant HDFN. In our study, the most frequent antibody other than D was anti-E (4.0%) in Rh blood group system. Anti-E does not usually cause HDFN, and if does so, it is mild in nature. Lewis antibodies are naturally occurring and usually IgM in nature, and reactive at or below room temperature. Lewis antibodies may be clinically relevant if causes in vitro haemolysis during serologic testing and in such cases antigen-negative blood should be selected for transfusion. One study conducted among healthy blood donors in Delhi, showed a prevalence of 0.09 per cent and the most frequent alloantibodies identified were from the MNS blood group system. A study conducted in Southern Thai population showed

| Blood group system | Alloantibody | Frequency (%) | Antibody specificity in male donors with history of blood transfusion | Antibody specificity in male donors without history of blood transfusion | Antibody specificity in female donors with pregnancy and blood transfusion | Antibody specificity in female donors with a history of pregnancy but no blood transfusion |
|--------------------|-------------|--------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| MNS                | Anti-M      | 51 (20.5)    | -                                                                   | 51                                                                  | -                                                                   | -                                                                   |
|                    | Anti-N      | 28 (11.0)    | -                                                                   | 28                                                                  | -                                                                   | -                                                                   |
|                    | Anti-S      | 8 (3.2)      | -                                                                   | 6                                                                   | 1                                                                   | 1                                                                   |
| Rh                 | Anti-D      | 18 (7.2)     | 2                                                                   | 3                                                                   | 4                                                                   | 9                                                                   |
|                    | Anti-C      | 8 (3.2)      | -                                                                   | 2                                                                   | 1                                                                   | 5                                                                   |
|                    | Anti-E      | 10 (4.0)     | -                                                                   | 9                                                                   | -                                                                   | 1                                                                   |
|                    | Anti-C<sup>+</sup> | 9 (3.7) | - | 8 | - | 1 |
|                    | Anti-c      | 6 (2.6)      | -                                                                   | 4                                                                   | -                                                                   | 2                                                                   |
| Kidd               | Anti-Jk<sup>a</sup> | 10 (4.0) | - | 9 | 1 | - |
|                    | Anti-Jk<sup>b</sup> | 11 (4.4) | 1 | 8 | - | 2 |
| Duffy              | Anti-Fy<sup>a</sup> | 13 (5.3) | 1 | 12 | - | - |
|                    | Anti-Fy<sup>b</sup> | 10 (4.0) | - | 9 | - | 1 |
| Kell               | Anti-K      | 10 (4.0)     | 1                                                                   | 7                                                                   | 1                                                                   | 1                                                                   |
|                    | Anti-Kp<sup>b</sup> | 7 (2.9) | - | 6 | - | 1 |
| Lutheran           | Anti-Lu<sup>a</sup> | 5 (2.1) | - | 5 | - | - |
| P                  | Anti-P1     | 10 (4.0)     | -                                                                   | 10                                                                  | -                                                                   | -                                                                   |
| Lewis              | Anti-Le<sup>a</sup> | 23 (9.3) | - | 23 | - | - |
|                    | Anti-Le<sup>b</sup> | 8 (3.2) | - | 6 | - | 2 |
| Multiple antibodies | Anti-D+K     | 2 (0.9)      | -                                                                   | -                                                                   | 2                                                                   | -                                                                   |
|                    | Anti-D+E    | 1 (0.5)      | -                                                                   | -                                                                   | 1                                                                   | -                                                                   |
| Total              |             | 248          | 5/211                                                               | 206/211                                                             | 11/37                                                               | 26/37                                                               |
the following antibodies, frequency-wise as most common - anti-Mi, anti-E, anti-Le, anti-c and anti-Le.

In the present study, only 30 donors (0.018%) had autoantibody as also reported earlier by Kaur et al (0.5%) and Tiwari et al (0.04%)\(^6\). In the present study, though we took detailed history about the aetiology of antibody formation, many alloantibodies were found in male blood donors. It has also been reported that in some cases the immune antibodies are found in non-transfused, healthy, male blood donors\(^6\).

Alloimmunization to red cell antigens is a challenge being faced in transfusion practices. The antibody screening in blood donors as well as in multi-transfused patients is necessary to improve the quality and safety of blood transfusion in the recipients. Additional large-scale studies are required to assess the need of antibody screening in healthy blood donors and to assess the clinical significance of the same.

**Financial support & sponsorship:** None.

**Conflicts of Interest:** None.

**References**

1. International Society of Blood Transfusion. Red cell Immunogenetics and Blood Group Terminology (working group). Blood group terminology. Amsterdam, the Netherlands: ISBT, 2017. Available from: http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/, accessed on February 13, 2019.

2. Walker SP. Identification of antibodies to red cell antigens. In: Roback JD, editor. Technical manual of American Association of Blood Banks (or AABB), 16th ed. Bethesda (MD): American Association of Blood Bank; 2008. p. 465-96.

3. National Blood Policy (National AIDS Control Organisation, NACO). Ministry of Health and Family Welfare. New Delhi: Government of India; 2007.

4. Pahuja S, Kushwaha S, Sethi N, Pujani M, Jain M. Screening of blood donors for erythrocyte alloantibodies. Hematology 2012; 17: 302-5.

5. Garg N, Sharma T, Singh B. Prevalence of irregular red cell blood antibodies among healthy blood donors in Delhi population. Transfus Apher Sci 2014; 50: 415-7.

6. Kaur D, Bains L, Kandwal M, Parmar I. Erythrocyte alloimmunization and autoimmunization among blood donors and recipients visiting a tertiary care hospital. J Clin Diagn Res 2017; 11: EC12-5.

7. Makroo RN, Rajput S, Agarwal S, Chowdhry M, Prakash B, Karna P. Prevalence of irregular red cell antibody in healthy blood donors attending a tertiary care hospital in North India. Asian J Transfus Sci 2018; 12: 17-20.

8. Promwong C, Siammai S, Hassarin S, Buakaew J, Yeela T, Soisangwan P, et al. Frequencies and specificities of red cell alloantibodies in the Southern Thai population. Asian J Transfus Sci 2013; 7: 16-20.

9. Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, et al. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion 2019; 59: 217-25.

10. Keokhamphoui C, Urwijitaroon Y, Kongphaly D, Thammanvong T. Red cell alloantibodies in Lao blood donors. Southeast Asian J Trop Med Public Health 2014; 45: 194-7.

11. Hashem AEA, Mostafa GMH, Faramawy MSM. Red blood cell alloantibodies in healthy Egyptian blood donors. Egypt J Hosp Med 2018; 72: 4913-8.

12. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med 1995; 119: 42-5.

13. Elhence P, Solanki A, Verma A. Red blood cell antibodies in thalassemia patients in northern India: Risk factors and literature review. Indian J Hematol Blood Transfus 2014; 30: 301-8.

14. Hamilton JR. Common and frequently encountered antibodies. Transfus Apher Sci 2009; 40: 189-94.

15. Myhre BA, Greenwalt TJ, Gajewski M. Incidence of irregular antibodies occurring in healthy donor sera. Transfusion 1965; 5: 350-4.

16. Beattie KM, Zuelzer WW. The frequency and properties of p+ dependent anti-M. Transfusion 1965; 5: 322-6.

17. Fung MK, Grossman BH, Hillyer CD, Westhoff CM. ABO, Lewis blood groups and structurally related antigens. Rh system and other blood group system. In: Technical Manual of American Association of Blood Banks, 18th ed. Bethesda, Maryland: American Association of Blood Banks; 2014. p. 304-51.

18. Tiwari AK, Pandey P, Sharma J, Shailja K, Dixit S, Raina V. Incidence of clinically significant antibodies in patients and healthy blood donors: A prospective cross-sectional study from a tertiary healthcare center in India. Transfus Apher Sci 2014; 50: 230-4.

19. Daniels G. Other blood groups. In: Roback JD, editor. Technical manual of American Association of Blood Banks (or AABB), 17th ed. Bethesda (MD): American Association of Blood Banks; 2011. p. 418-20.

---

*For correspondence:* Dr Tulika Chandra, Department of Transfusion Medicine, King George’s Medical University, Lucknow 226 003, Uttar Pradesh, India

e-mail: drtulikachandra@gmail.com